Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.

Trial Profile

Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PROMISE
  • Sponsors AbbVie
  • Most Recent Events

    • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top